Schimmel Michael S, Bromiker Ruben, Soll Roger F
Department of Neonatology, Shaare Zedek Medical Center, Jerusalem 91031, Israel.
Clin Perinatol. 2004 Sep;31(3):545-53, ix-x. doi: 10.1016/j.clp.2004.04.020.
In clinical practice, neonatal polycythemia has been used as a marker for neonatal hyperviscosity, implicated as a cause of long-term neurologic delay and damage in the growing child. Clinicians have focused on the newborn infant's hematocrit (Hct) level as the criterion for therapeutic intervention. Partial exchange transfusion is traditionally used as the method to lower the Hct and treat hyperviscosity; however, it is unclear whether this is an effective approach in preventing the long-term neurologic consequences. This article re-evaluates this clinical approach to the diagnosis and treatment of neonatal polycythemia and suggests that this controversial therapy needs re-evaluation.
在临床实践中，新生儿红细胞增多症一直被用作新生儿高黏滞血症的一个指标，被认为是儿童成长过程中长期神经发育延迟和损伤的一个原因。临床医生一直将新生儿的血细胞比容（Hct）水平作为治疗干预的标准。传统上采用部分换血疗法来降低血细胞比容并治疗高黏滞血症；然而，目前尚不清楚这是否是预防长期神经后果的有效方法。本文重新评估了这种诊断和治疗新生儿红细胞增多症的临床方法，并表明这种有争议的治疗方法需要重新评估。
